Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target

Benzinga · 2d ago
Morgan Stanley analyst Terence Flynn reinstates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and announces $665 price target.